Contributions
Abstract: P618
Type: Poster Sessions
Abstract Category: Therapy - Risk management for disease modifying treatments
Objectives: To compare the liver safety profile of interferon β (IFN β) and teriflunomide in patients with multiple sclerosis
Methods: A systematic review of literature and network meta-analysis was carried out following the Cochrane Collaboration methodology. All randomised, double-blind, single-blind, or open-label, as well as cross-over trials, comparing all types of IFN β with teriflunomide, or either drug with glatiramer acetate, natalizumab, alemtuzumab, fingolimod, daclizumab, or placebo in participants with RRMS were included. Studies involving patients with secondary progressive multiple sclerosis (SPMS) were excluded. An indirect comparison network meta-analysis within a Bayesian framework with STATA (version 13.0) was done for this study. We summarised the results of network meta-analysis with effect sizes (OR) and their confidence intervals (95% CI).
Results: The database searches yielded 284 titles, with 15 records as duplicates. One study was identified by manually searching. Thirteen articles were included in the systematic review. Twelve studies compared IFN β (4203 patients) vs another DMT. Four studies evaluated the effectiveness and safety of teriflunomide (906 patients) vs another DMT. Six studies reported drug-induced liver injury as per the Hy's Law. However, only one study had a direct comparison and reported no cases of liver toxicity in either group, so it was not possible to estimate the OR. The indirect comparisons metanalysis shows that there was no statistically-significant difference between teriflunomide and IFN β (OR 1.09, 95% CI 0.02-2.16).
Conclusions: There were no significant difference when comparing IFN β and teriflunomide in terms of liver failure or elevation of transaminases. Even though there was evidence that patients of with teriflunomide, compared to IFN β, had an increased risk of having a liver function test alteration, it is difficult to provide a meaningful interpretation given that the liver tests evaluated and cut-off points used varied widely from study to study
Disclosure: This article was financed with resources from Sanofi Colombia Ltd, who had no role in the design and implementation of the project
Abstract: P618
Type: Poster Sessions
Abstract Category: Therapy - Risk management for disease modifying treatments
Objectives: To compare the liver safety profile of interferon β (IFN β) and teriflunomide in patients with multiple sclerosis
Methods: A systematic review of literature and network meta-analysis was carried out following the Cochrane Collaboration methodology. All randomised, double-blind, single-blind, or open-label, as well as cross-over trials, comparing all types of IFN β with teriflunomide, or either drug with glatiramer acetate, natalizumab, alemtuzumab, fingolimod, daclizumab, or placebo in participants with RRMS were included. Studies involving patients with secondary progressive multiple sclerosis (SPMS) were excluded. An indirect comparison network meta-analysis within a Bayesian framework with STATA (version 13.0) was done for this study. We summarised the results of network meta-analysis with effect sizes (OR) and their confidence intervals (95% CI).
Results: The database searches yielded 284 titles, with 15 records as duplicates. One study was identified by manually searching. Thirteen articles were included in the systematic review. Twelve studies compared IFN β (4203 patients) vs another DMT. Four studies evaluated the effectiveness and safety of teriflunomide (906 patients) vs another DMT. Six studies reported drug-induced liver injury as per the Hy's Law. However, only one study had a direct comparison and reported no cases of liver toxicity in either group, so it was not possible to estimate the OR. The indirect comparisons metanalysis shows that there was no statistically-significant difference between teriflunomide and IFN β (OR 1.09, 95% CI 0.02-2.16).
Conclusions: There were no significant difference when comparing IFN β and teriflunomide in terms of liver failure or elevation of transaminases. Even though there was evidence that patients of with teriflunomide, compared to IFN β, had an increased risk of having a liver function test alteration, it is difficult to provide a meaningful interpretation given that the liver tests evaluated and cut-off points used varied widely from study to study
Disclosure: This article was financed with resources from Sanofi Colombia Ltd, who had no role in the design and implementation of the project